Flu vaccine after a heart attack or unstable angina
Official title: Influenza Vaccination After Acute Coronary Syndrome
Run by Tongji Hospital · NCT07259252 · Data updated 2026-11-12
This trial will test whether giving a flu shot to adults aged 18–80 who recently had acute coronary syndrome lowers the chance of future heart attacks, stroke, or death.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years to 80 Years |
| Sex | All |
| Enrollment | 6620 (estimated) |
| Sponsor | Tongji Hospital Academic / other |
| Locations | 1 site (Wuhan, Hubei) |
| Status | Recruiting |
| Started | December 3, 2025 |
| Main results expected | March 30, 2029 |
| Study ends | March 30, 2029 |
| Registry record updated | January 13, 2026 |
| Trial ID | NCT07259252 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults aged 18–80 who were hospitalized for acute coronary syndrome, can give written informed consent, have not received an influenza vaccine in the past year, and have no contraindications to the vaccine are ideal candidates.
✕Probably not a fit
Patients with life expectancy under one year, recent influenza vaccination, contraindications to the influenza vaccine, or serious comorbid conditions are less likely to receive benefit from participation.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This interventional study enrolls adults (18–80) with acute coronary syndrome and assigns them to receive either an influenza vaccine or a placebo shortly after hospital discharge. Investigators will track major cardiovascular events including cardiovascular death, myocardial infarction, and stroke, as well as secondary outcomes such as all-cause death, unplanned revascularization, heart-failure or arrhythmia hospitalizations, and stent thrombosis. Follow-up is conducted by phone at 1 month, 3 months, 6 months, and 12 months after discharge. The goal is to determine whether post-ACS influenza vaccination reduces subsequent adverse cardiac outcomes in a Chinese patient population.
Why it matters
Potential benefit: If successful, this approach could reduce cardiovascular deaths, heart attacks, strokes, and other serious cardiac complications after acute coronary syndrome.
How similar studies have gone: Previous randomized trials and meta-analyses have suggested influenza vaccination can lower cardiovascular events and mortality after cardiac events, so this approach has supporting evidence but is still being tested in different populations.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. ACS patient aged from 18 to 80 years. 2. Volunteer for the study and written informed consent. Exclusion Criteria: 1. Participate in any drug clinical trials within 3 months. 2. Patients with life-threatening complications, or the researchers determined that the survival time of patients with no more than 1 years. 3. Serious neurological disease (Alzheimer's disease, Parkinson syndrome, progressive lower limbs or deaf patients). 4. Previous history of cancer or tumor, or pathological examination confirmed precancerous lesions (such as breast ductal carcinoma in situ, or atypical hyperplasia of the cervix). 5. Patients refused to comply with the requirements of this study to complete the research work. 6. Patients Received influenza vaccination within 1 year. 7. Patients with contraindications for influenza vaccination.
Where it's running
-
Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology
Wuhan, Hubei, China Recruiting
Study contacts
- Principal investigator: Dao Wen Wang — Tongji Hospital
- Study coordinator: Yang Sun
- Email: sunyang.7@163.com
- Phone: +86-15527674573
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Risk of malignant arrhythmias after acute coronary syndrome
This study tracks how often dangerous heart rhythms occur in adults admitted for ACS and looks for patterns that might predict them.
-
Drug-coated balloons vs drug-eluting stents for immediate slow-flow/no-reflow in STEMI with high thrombus
This study tests whether using a drug-coated balloon instead of a drug-eluting stent during PCI helps reduce immediate slow-flow or no-reflow in STEMI patients with high thrombus burden.
-
New prodrug CG-0255 Besylate vs Plavix in healthy adults
This study tests whether CG-0255 Besylate works similarly to Plavix® in healthy adults to understand how the two drugs behave in the body.
-
Biomarker patterns in ACS patients with pneumonia and COPD after flu vaccination
This study tests whether certain blood biomarkers change in people with acute coronary syndrome who also have pneumonia and COPD, and whether flu vaccination affects those biomarker levels.
-
Prehospital High-Sensitivity Troponin I to rule out heart attack for EMS patients
EMS patients with chest pain or possible heart symptoms are being studied to see if a portable hs-TnI test in the ambulance can help identify those at low risk for a heart attack.
-
IVUS-guided versus angiography-guided stent placement for acute coronary syndrome
This test will see if using intravascular ultrasound (IVUS) to guide stent placement helps adults with acute coronary syndrome more than standard angiography-guided PCI.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.